logo
NasdaqGS:ROIV logo

Roivant Sciences Community

NasdaqGS:ROIV Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

ROIV logo
Roivant Sciences
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts

Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain

Key Takeaways Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas. Potential in-licensing and late-stage pipeline approvals could significantly enhance earnings and portfolio sales impact.
View narrative
US$16.14
FV
31.7% undervalued intrinsic discount
59.17%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
3 months ago author updated this narrative